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Summary 
Neutral endopeptidase (NEP; EC.  3.4.24.11) is a type 2 cell surface metalloprotease known by 
a variety of eponyms, including enkephalinase,  common acute lymphoblastic leukemia antigen, 
and CD10.  Identified  substrates are largely neural  or humoral  oligopeptide agonists,  and the 
enzyme functions  to  terminate  signaling  by degrading  the ligand,  analogously to acetylcho- 
line/acetylcholinesterase.  Targeted disruption of the NEP locus in mice results in enhanced lethality 
to endotoxin shock with a pronounced gene dosage effect. The site(s)  of action appears down- 
stream from release of tumor necrosis factor and interleukin-1  since NEP-deficient animals dem- 
onstrate increased sensitivity to these mediators  as well.  This unexpected finding indicates an 
important  protective role for NEP in septic shock. 
p eptide  signaling  molecules  are  controlled  at  the  level 
of synthesis and release. Another level of control can exist 
through their degradation,  analogous to the elimination of 
acetylcholine by acetylcholinesterase. Neutral endopeptidase 
(NEP) appears particularly well suited as a model system for 
studies of proteolytic control of biologically active peptides 
(1). NEP is a member of a newly recognized family of metallo- 
proteinases that includes the endothelin-converting  enzyme 
and the Kjell blood group  antigen  (2).  The  NEP enzyme 
is colocalized with peptidergic neurons in the central nervous 
system, along mucosal epithelial surfaces,  and in the brush 
border membrane of the kidney. Pre-B cell expression of NEP 
was first noted as the common acute lymphoblastic leukemia 
antigen,  a marker for a childhood leukemia (3, 4). Inflam- 
matory cells such as the PMN are also positive for NEP ex- 
pression  (5). 
Highly specific,  rationally designed NEP inhibitors  such 
as thiorphan  (6) have been used as pharmacologic tools, and 
they potentiate the activity of particular peptide agonists, in 
some cases, by several orders of magnitude. Such studies have 
identified two broad classes of substrates subject to NEP con- 
trol in vivo, neuropeptides including enkephalins,  tachykinins, 
and bombesin-like peptides (7-9), and humoral mediators in- 
cluding bradykinin,  atriopeptin,  and endothelins  (10-12). 
In the present report, we characterize mice that bear a tar- 
geted disruption of the NEP gene in two models of shock. 
The models were chosen because of the wide variety of poten- 
tial NEP substrates  that  may be present  in  septic shock. 
Materials and Methods 
Gene  Targeting of the NEP Locus.  A murine Sv 129 genomic 
library was screened with the human NEP cDNA, resulting  in 
multiple overlapping clones. A 6.5-kb genomic fragment containing 
exons 10-14 was digested with Bglll, and the 0.6-kb fragment was 
replaced with a neomycin resistance cassette driven by the gluco- 
kinase promoter. 
The targeting  fragment  was subcloned into  the pPNT vector 
(13) for positive/negative selection with geneticin and gancyclovir. 
Electroporation into J1 ES cells (,~107 cells, 16 #g targeting vector, 
400 V at 25/tF) was followed by plating on 75 cm  2 of neomycin- 
resistant primary embryonic fibroblasts derived from Sv 129 mice 
homozygous  for/~2-microglobulin deficiency and irradiated with 
2,400 rod. 12 h after electroporation, confluent ES cells were passed 
1:4 after brief trypsin treatment and were plated on irradiated feeders 
cells. Selection was initiated with 0.5 mg/ml geneticin and 2/~M 
gancyclovir. On day 8,  200 resistant clones were picked with a 
micropipette and were expanded. Approximately 3% of clones were 
correctly targeted and were introduced into C57B1/6 blastocysts. 
Chimeric males were bred with C57B1/6 females to yield germ 
line transmission of the targeted allele. Heterozygous progeny were 
inbred yielding littermates  used in these experiments. 
Biochemical and Biological Assays.  NEP enzymatic activity was 
assayed fluorometrically using glutaryl-Ala-Ala-Ala-Phe-jS-naphthyl- 
amide in a two-stage assay  using aminopeptidase M (5), as described 
in  the  legend  of Fig.  2.  Renal  membranes  were  prepared  by 
homogenization of kidneys in 10 mM Tris-HC1, pH 7.5, containing 
0.2 M sucrose, followed by centrifugation.  Membranes obtained 
from a 20,000 g pellet were resuspended in 100 mM morpholino- 
ethanesulfonate buffer, pH 6.5, containing  300 mM NaC1. 
Endotoxin lipopolysaccharide (Salmonella enteriditis, L6011; Sigma 
Chemical Co., St. Louis, MO) plus 8 mg D-galactosamine/20 g 
body wt were injected i.p. at time 0 into male littermates  at 8-10 
wk of age, ~2.5  h  into  the animals' light  cycle (14). TNF-c~ 
(CS064071; R&D Systems, Minneapolis, MN) and IL-1B (BN024071; 
R&D Systems) were injected via the tail vein in similar groups. 
Lethality was assessed after 24 h. In the endotoxin  experiments, 
wild-type mice (19 total, minimum  of 3 per dose), NEP heterozy- 
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Volume 181  June 1995  2271-2275 Figure  1.  Gene targeting of the neutral endopeptidase locus.  (A) Re- 
striction map of the murine NEP locus encompassing  exons 10-17,  tar- 
geting vector, and predicted map following homologous recombination. 
Homologous recombination introduces a new BamHl site into the gene, 
which can be detected with the flanking probe A (Ram, BamHI; Bgl, BgllI; 
E, EcoKl; H, Hindlll; Xba, Xbal; Xho, XhoI).  (B) Southern analysis 
of a representative litter by tait snip DNA digestion with BamH1.  The 
wild-type allele migrates at 15.3 kb, while the replacement of exon 13 
yields a 11.4-kb fragment with flanking probe A. (C) Northern analysis 
of renal poly(A  +)  KNA ('~5 #g) from NEP  (-/-)  and (+/+)  litter- 
mates. (Upper  panel) The "knockout" mouse does not display a detectable 
NEP message using a cDNA probe (~o500-bp EcoRI fragment) spanning 
the active site region, exons  14-20, while a series of mKNAs that cor- 
respond  to multiple different  5' and 3' untranslated regions are seen in 
the wild type (18-h exposure,  -70'C) (28).  (Lower  panel) Kehybridiza- 
tion of the membrane with cDNA corresponding to ~-actin indicates similar 
amounts of RNA in each lane (2-h  exposure,  -70~ 
gotes  (+/-)  (34  total),  and  NEP  homozygous  deficient (-/-) 
(33 total) animals were housed under barrier conditions. All an- 
imal experiments and animal care procedures were performed under 
the  guidelines of Children's  Hospital  (Boston,  MA).  Other  ex- 
perimental details are given in the  figure legends. 
Statistical  Analysis.  Multiple logistic regression was used to assess 
the significance of dose and gene copies for risk factors of death. 
The probability of death was modeled as a function  of LPS and 
gene doses, with LPS dose as a continuous variable and gene dose 
as a categorical covariate with three levels (i.e., none, one, or two 
Figure  2.  Enzymatic analysis of neutral endopepti- 
dase littermates. Renal membranes  were suspended  in 
100 mM MES buffer, pH 6.5, containing 300 mM NaCI 
with or without 1/~M phosphoramidon. Glutaryl-Ala- 
Ala-Phe-MNA (100 #M) was incubated with enzyme 
for 30 min at 37~  and the reaction was terminated 
with boiling. The mixture was next treated with 6 mU 
aminopeptidase M at 37~  for 30 rain. Aliquots of the 
reaction were assayed for relative fluorescence (extinc- 
tion  =  340  nm, emission  =  425  nm). 
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Figure  3.  Lethal  toxicity  of LPS in neutral  endopeptidase  transgenics. 
Transgenic littermates  (male, 8-10 wk old) were sensitized  with  8 mg of 
o-galactosamine and the indicated  i.p. dose of LPS (S.  enteritidis, Sigma 
L6011) calculated  per 20 g body  wt. Mortality  was recorded  for 24 h after 
dosing￿9 
alleles). A main effects model was fitted and the likelihood ratio 
test was used to evaluate  each risk factor￿9  Odds ratios  were calcu- 
lated to compare risks between the three genotype groups￿9  LDs0 
was estimated by probit analysis￿9 
Results and Discussion 
To extend our insight into the in vivo functions of this 
protease,  the routine NEP gene was disrupted by replacing 
exon 13 and part of intron 13 with a gene encoding neomycin 
resistance (hen  ~) in a 6.5-kb targeting vector (Fig. 1 A). Elec- 
troporation into J1 embryonic stem (ES) cells was followed 
by positive/negative selection with geneticin and gancyclovir. 
The correct targeting event was detected in 6 out of 200 ES 
cell clones that were screened. After blastocyst injection, mu- 
tant alleles were identified in the resulting chimeric mice and 
through the germline F1 animals￿9 Heterozygous NEP (-/+) 
animals were bred to generate homozygous NEP-deficient 
(-/-)  animals. The mutated allele was found in the expected 
Mendelian ratios, indicating no enhanced prenatal mortality 
(Fig.  1 B). 
The transgenic NEP  (-/-)  mice were grossly develop- 
mentally normal, although subtle differences in lymphoid de- 
velopment were observed (15). To confirm the abrogation 
of NEP activity in the targeted animals, Northern analyses 
and enzymatic assays were performed (Figs￿9  1 C  and 2) using 
renal tissues as a rich source of enzyme message and protein. 
Using a probe containing the known active site of the en- 
zyme, we detected no NEP mRNA in the targeted animals. 
In addition, virtually all phosphoramidon-sensitive estero- 
lytic activity was absent in crude renal membranes from the 
NEP (-/-)  strain (Fig. 2). The low level of phosphoramidon- 
insensitive enzymatic activity observed is likely a reflection 
of additional (non-NEP)  metalloprotease activity (16). 
Figure  4.  Hepatic  pathology  after LPS shock. Representative  hema- 
toxylin  and eosin  sections  of hepatic  tissues  in LPS shock. (A) Wild type, 
no LPS/galactosamine.  (B and C ) Livers  from  wild-type  and NEP-deficient 
animals, respectively,  5 h after 10 mg LPS + 8 mg o-galactosamine/20  g 
body  wt. Note  the hemorrhagic  necrosis  in the NEP-deficient  (-/-) animal 
(originally x40). 
Because of the role of NEP in terminating the actions of 
a wide variety of proinflammatory peptides, we challenged 
mice with endotoxin LPS and I)-galactosamine. LPS is a com- 
plex inflammatory  stimulus that activates parallel proinflamma- 
tory humoral pathways including the coagulation, kininogen, 
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to release cytokines, including TNF and IL-1 (17, 18). NEP- 
deficient ( -/-  ) animals demonstrated >10-fold increased sen- 
sitivity to endotoxin relative to wild-type littermates  (Fig. 
3). There was a highly significant effect of dose on mortality 
(likelihood ratio test  =  13.49 on 1 d.f., P <0.001),  as well 
as the number of gene copies on mortality (likelihood ratio 
test  =  32.21 on 2 d.f., P <  0.001). Probit analysis revealed 
an LDs0 of 1.2/zg for NEP (-/-)  animals, 6.7 gg for NEP 
(-/+) heterozygotes, and >16.7 gg for wild-type NEP (+/+) 
mice.  Homozygous NEP deficient  mice were >100  times 
more likely to die than wild-type mice (odds ratio  =  127.82, 
P <0.001); heterozygotes were almost 25 times more likely 
to die than wild type (odds ratio  =  24.36, P <0.01); gene- 
deleted animals were five times as likely to die as heterozy- 
gores (odds ratio  =  5.25, P <0.01). At the time of autopsy, 
the knockout animals  had gross discoloration  (blue black) 
of the liver, as did the (-/+) heterozygotes. Histopathologic 
analysis revealed diffuse hemorrhagic necrosis in these livers, 
but not in the livers of their wild-type littermates (Fig.  4). 
Additionally, both wild-type and NEP ( -/-  ) mice that were 
given LPS or D-galactosamine alone did not show evidence 
of gross pathology. 
No differences were observed in the coagulation profile in 
endotoxin-treated  wild-type or knockout  animals  (throm- 
bocytopenia, elevated coagulation times, elevated fibrin split 
products;  data not shown).  To determine whether the ob- 
served sensitivity to LPS-induced shock occurred in parallel 
or downstream from cytokine release, mice were injected with 
the combination of TNF-ot and IIr  (1 and 0.5 gg, respec- 
tively) (Table  1) (19).  A  marked difference in susceptibility 
to this combination was also observed for NEP (-/-)  mice. 
While all  of the NEP-deficient  animals  that  were injected 
succumbed to this cytokine mixture,  only one of six wild- 
type mice developed irreversible shock. Thus, the enhanced 
lethality  to  galactosamine-sensitized  endotoxin  shock  is 
carried  over  in  a  model  using  the  more defined  stimulus 
TNF-ot + IL-I~. Given the complexity of the endotoxin re- 
sponse,  these  results  confirm  a  critical  role  for  NEP  in 
modulating  circulatory  shock states.  Clearly,  since neither 
TNF-o~ nor IblB is a substrate for the protease, the data in- 
dicate that these cytokines must stimulate release and poten- 
tially upregulation of additional NEP-sensitive peptides that 
Table  1.  Lethal Toxicity of TNF-ot  +  IL-lfl in 
NEP Transgenics 
Lethality 
Genotype  TNF-ce  _+  IL-1B  (deaths/total) 
mg 
Wild type ( + / +)  1.0  _+ 0.5  1/5 
NEP  ( -  / -  )  1.0  _+  0.5  6/6 
Male mice (8-10 wk old) were treated with recombinant mouse TNF-c~ 
and IL-I~. The mixture of both reagents in 0.15 ml saline was ad- 
ministered via the tail vein. The mice died within 5-12 h after dosing. 
The two-tailed probability based on Fisher's exact test indicates a sig- 
nificantly higher proportion of death in the gene-deleted group (P  = 
0.015). 
enhance lethality.  The potentiation of lethal shock is likely 
caused by a complex interplay of NEP substrate peptides that 
are released in shock states, including endothelin, bradykinin, 
tachykinins,  atriopeptin, and enkephalins  (20-23). These pep- 
tides are capable of acting synergistically to cause ischemia, 
hemoconcentration,  and vascular permeability changes that 
would contribute  to the perfusion  defects in  shock states. 
The significant gene dosage effect noted in heterozygous 
deficient animals upon LPS challenge indicates that NEP en- 
zyme levels in vivo operate near saturation  in shock states. 
Heterozygous phenotypes consistent with gene dosage effects 
have also been seen with endothelin-1 and G-CSF gene dis- 
ruption  (24,  25). 
NEP  (-/-)  animals  at  LD100 for  LPS  were  protected 
from lethal  shock by i.p.  injection  of recombinant  human 
NEP (Lu, B., unpublished observation). The metaUoprotease 
that processes TNF to its mature form is related but not iden- 
tical to NEE based on the inhibitor profile (26-28). Inhibi- 
tion of this enzyme afforded protection against lethal endo- 
toxin shock,  indicating  that  zinc metalloproteases regulate 
both pro-  and antiinflammatory  pathways. 
Mice genetically deficient in NEP will also be useful for 
understanding the role of this enzyme in pain pathways (29), 
neurogenic  inflammation  (30,  31),  and lymphoid develop- 
ment  (32). 
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